Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4229 trials
Conditions Primary Aldosteronism, High Blood Pressu...
Phase Not Applicable
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this observational study is to see if there is a cyclical or exaggerated diurnal variation in aldosterone production in people with Primary Aldosteronism.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Sensitivity and specificity of 24 hour urine tetrahydroaldosterone excretion. (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2023-02-24
Completion: 2027-07-24
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Queen Mary University of London
Principal Investigators:
  • William Drake, Prof (PRINCIPAL_INVESTIGATOR) - Queen Mary University of London
Contact Information
Study Contact:
Yun Ni Lee
+442078827275
y.n.lee@qmul.ac.uk
Tumi Kaminskas
+442078827275
research.governance@qmul.ac.uk
Yun Ni Lee
y.n.lee@qmul.ac.uk
Queen Mary University of London
Interventions
N/A
Study Locations (1 sites)
Queen Mary University of London, London, United Kingdom
Eligibility Criteria
Inclusion Criteria: * People with clinically suspected PA but have not met criteria for diagnosis. Suspicion based on low-renin (renin activity \<0.5 nmol/h/L or renin mass \<5 ng/L), plasma sodium \> 140mmol/L or plasma potassium \< 4mmol/L. * Patients who have been diagnosed with PA and had previous aldosterone samples \<277 pmol/L, a level which would normally not qualify for confirmatory testing. * Patients with aldosterone results done at different times that indicate variability in production. * Willing to consent and participate in the study. Exclusion Criteria: * Inability to withdraw β-adrenoceptor antagonist therapy for 2 weeks. * People on end of life treatment.
Conditions Hypertension
Phase NA
Enrollment 930
Locations 2 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Nearly half of adults in the United States (47 percent, or 116 million) have hypertension, also known as high blood pressure (BP). Uncontrolled high BP can be devasting as it can lead to stroke, heart attack and kidney failure, as well as other numerous health conditions. Hypertension can be controlled; however, only one in four of adults with hypertension have their BP controlled. The chance of having high BP increases as one ages, requiring the need to examine effective hypertension strategies in older adults. The issue of hypertension management is compounded even further among older U.S. adults who live with multiple chronic diseases. National organizations identified several effective health systems strategies for improving rates of BP control, including patient self-measured blood pressure (SMBP) monitoring. SMBP involves a patient's regular use of personal BP monitoring devices to assess and record BP across different points in time, typically at home. The evidence base for utilizing SMBP strategies in healthcare systems and practices is strong. However, there is not research regarding SMBP including how to include it into workflow in primary care clinics. Previous research has shown SMBP is beneficial, but more information is needed regarding whether SMBP is beneficial in high-risk populations (such as rural, older adults or Black, older patients). The research team will test whether SMBP with normal clinical support vs SMBP with clinical pharmacist support improves BP in older adults living with multiple chronic conditions. The addition of a pharmacist has been shown to improve patient outcomes, though the effectiveness of SMBP with a clinical pharmacist in older adults is not known. The primary outcome will be change in systolic BP over 12 months. The secondary outcome will be self-reported treatment burden over 12 months, using a validated tool called the Multimorbidity Treatment Burden Questionnaire. The research team plans to include a subgroup of rural, older adults and Black, older adults and will not exclude older adults who have dementia.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: SMBP with clinical pharmacist support — Self-measured blood pressure with clinical pharmacist support

Primary Outcomes

  • Systolic blood pressure (Baseline and 12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-07-01
Completion: 2031-05-01
Eligibility
Age: 65 Years and older
Sex: ALL
Volunteers: false
Enrollment: 930 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Korey Kennelty
Contact Information
Study Contact:
Korey Kennelty, PharmD, PhD
319-335-8862
korey-kennelty@uiowa.edu
Korey Kennelty, PharmD, PhD
319-335-8862
korey-kennelty@uiowa.edu
University of Iowa
Interventions
  • Behavioral: SMBP with clinical pharmacist support — Self-measured blood pressure with clinical pharmacist support
Study Locations (2 sites)
University of Iowa Health Care, Iowa City, Iowa 52242 United States
University of Iowa, Iowa City, Iowa 52242 United States
Eligibility Criteria
Inclusion Criteria: * The patient is at least 65 years of age * Patient is seen at least once in clinic or healthcare system in the previous 12 months * Patient has a six-month average (non-acute/maintenance) systolic blood pressure (SBP) \>= 145 mmHg, documented in the electronic medical record in last six months * Patient has a baseline in-clinic visit systolic blood pressure (SBP) \>= 140 mmHg * Patient plants to receive care from participating healthcare system for the next 24 months Exclusion Criteria: * The patient is enrolled in hospice or has an active referral to hospice care * The patient resides in a nursing home, in skilled nursing, rehabilitation facility, or memory care * The patient is not capable of providing informed consent * The patient is unable to communicate in English or Spanish * The patient is in active chemotherapy or radiation treatment for cancer * The patient is pregnant or has plans to become pregnant * The patient is currently participating in another study focused on blood pressure * The patient does not have a telephone
Conditions Idiopathic Intracranial Hypertension (II...
Phase NA
Enrollment 114
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This study is aimed at patients suffering from recently discovered intracranial hypertension, caracterized by visual loss, chronic headache and/or tinnitus. The goal is to evaluate if stenting of a specific vein in the brain could decrease the hypertension and improve associated symptoms. Patients will be randomly assigned in either best medical care group (recommended medication associated with weight loss) or interventional group (best medical car + stenting of the specific vein) and will undergo specific follow-up visits after 1, 3 and 12 months.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Best medical care — Acetazolamide will be introduced at the time of papilledema discovery. Weight loss will be recommended.
  • Device: Intervention (stenting) — Transverse venous sinus will be stented by neuro-radiological intervention

Primary Outcomes

  • Rate of patients with resolved papilledema and normalization of intra-cranial pressure (3 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-09-19
Completion: 2029-04-30
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 114 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University Hospital, Montpellier
Collaborators: Ministère de la Santé
Contact Information
Study Contact:
Anne DUCROS, MD, PhD
+33 467 339 469
a-ducros@chu-montpellier.fr
Fédérico CAGNAZZO, MD, PhD
+33 467 337 532
f-cagnazzo@chu-montpellier.fr
Anne DUCROS, MD, PhD
+33 467 339 469
a-ducros@chu-montpellier.fr
CHU de Montpellier Hôpital Gui de Chauliac
Interventions
  • Drug: Best medical care — Acetazolamide will be introduced at the time of papilledema discovery. Weight loss will be recommended.
  • Device: Intervention (stenting) — Transverse venous sinus will be stented by neuro-radiological intervention
Study Locations (3 sites)
CHU de Montpellier Hôpital Gui de Chauliac, Montpellier, 34295 France
CHU de REIMS, Reims, 51092 France
CHU de Toulouse, Toulouse, 31000 France
Eligibility Criteria
Inclusion Criteria: 1. Subject is ≥ 18 years old at inclusion. 2. Subject with definite new diagnosis (˂ 3 months) of IIH satisfying the modified Dandy criteria (A to E) 3. Subject with intracranial TVS stenosis on dominant transverse sinus and hypoplastic contralateral one (or bilateral TVS stenosis) diagnosed on MRI 4. Normal MRI findings excepted intracranial TVS stenosis or IIH related abnormalities 5. Subject with ophthalmologic IIH symptoms and signs (RNFL ≥ 130 µm, Frisen score ≥ 2, and absence of differential diagnostic) 6. Subject without macular ganglion cells atrophy seen on OCT 7. Patient having received information about data collection and having signed and dated an Informed Consent Form 8. Subjects must be able to attend all scheduled visits and to comply with all trial procedures 9. Subjects must be covered by public health insurance Exclusion Criteria: 1. Subject previously treated with acetazolamide for IIH 2. Known contrast product, Nickel, titanium allergy 3. Exposure to an oral drug, substance, or disorder that has been associated with elevation of intracranial pressure within 2 months of diagnosis (lithium, vitamin A, tetracycline and related compounds) 4. History of intracranial venous thrombosis or intracranial neoplasia 5. Fulminant decrease of visual acuity due to the IIH defined as a visual loss (of the most seriously impaired eye) of at least 3/10 (from corrected vision) within 4 weeks, in absence of any other ophthalmologic pathology and Mean Deficit of visual field superior to -10 dB 6. Macular ganglion cells atrophy seen on OCT 7. Optic nerve atrophy 8. Amblyopia 9. Refractive error greater ±8 sphere or more than ±3 in cylinder in either eye if there are abnormalities in funduscopy (optic disc tilt, staphyloma), previous glaucoma, other disorders causing visual loss 10. Pregnancy: if a woman is of childbearing potential a urine or serum beta HCG test is positive 11. Patient with a severe or fatal comorbidity that will likely prevent improvement or follow-up or that will render the procedure unlikely to benefit the patient. 12. Evidence of intracranial hemorrhage (subarachnoid hemorrhage (SAH), intracerebral hemorrhage (ICH), etc.) 13. Life expectancy under 6 months 14. Chronic IIH 15. Patients with renal failure (creatinine \> 1.5 mg/dl and/or creatinine clearance \< 60 mL/min, except if patient is already on hemodialysis) 16. History of previously implanted intra-cranial sinus stent 17. Previous gastric bypass surgery 18. Contra-indication to general anesthesia 19. Contra-indication to aspirin, clopidogrel or other P2Y12 anti-aggregant 20. History of chronic obstructive pulmonary disease or other severe respiratory disease 21. History of deep vein thrombosis or pulmonary embolism 22. History of atrial fibrillation or other risks of stroke 23. Cerebral vascular lesions (arteriovenous malformation, arteriovenous fistula, aneurysms, significant stenosis of extra- or intra-cranial vessels other than the targeted venous sinus stenosis, intracranial artery dissection, etc.). 24. Anatomical anomaly of the venous sinus which would prevent safe catheterization and stenting 25. Subject who are in a dependency or employment with the sponsor or the investigator 26. Participation in another clinical trial or administration of an unapproved drug within the last 4 weeks before the screening date 27. Subject protected according to the French Public Health Code (e.g. patients under law protection, prisoners, pregnant, parturient or lactating women, and patients under guardianship/curatorship)
Conditions Young Adult, Hypertension in Pregnancy, ...
Phase Not Applicable
Enrollment 200
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The purpose of this study is to understand more about why young people who were born to a hypertensive pregnancy may have increased risk of high blood pressure and are often at increased risk of heart and blood vessel disease later in life.

Design

Study type: Observational Observational model: Cohort Time perspective: Other

Interventions / Regimen

  • Other: History of being born to hypertensive or normal pregnancy — CLARITY is an observational study whereby participants will attend one 4-hr visit the Division of Cardiovascular Medicine, University of Oxford at the John Radcliffe Hospital in Oxford, with the option to split the study visit over two days for convenience. Participants will be invited by the ALSPAC study team to attend a study visit in Oxford where the investigators will use MRI and other imaging modalities to study the brain, heart, liver, kidneys, and vasculature using standardised protocols. A dataset including information from previous follow-up of these cohorts and the detailed pregnancy data available within ALSPAC will be generated by the study team in Bristol and integrated with available data from the Oxford cohorts.

Primary Outcomes

  • Cardiac right ventricular mass (30-40 years of old)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2022-11-17
Completion: 2027-01-31
Eligibility
Age: 30 Years – 40 Years
Sex: ALL
Volunteers: false
Enrollment: 200 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Oxford
Collaborators: University of Bristol
Principal Investigators:
  • Adam J Lewandowski (PRINCIPAL_INVESTIGATOR) - Cardiovascular Clinical Research Facility
Contact Information
Study Contact:
Katie Suriano
01865 226845
clarity@cardiov.ox.ac.uk
Katie Suriano
01865 226845
clarity@cardiov.ox.ac.uk
University of Oxford
Interventions
  • Other: History of being born to hypertensive or normal pregnancy — CLARITY is an observational study whereby participants will attend one 4-hr visit the Division of Cardiovascular Medicine, University of Oxford at the John Radcliffe Hospital in Oxford, with the option to split the study visit over two days for convenience. Participants will be invited by the ALSPAC study team to attend a study visit in Oxford where the investigators will use MRI and other imaging modalities to study the brain, heart, liver, kidneys, and vasculature using standardised protocols. A dataset including information from previous follow-up of these cohorts and the detailed pregnancy data available within ALSPAC will be generated by the study team in Bristol and integrated with available data from the Oxford cohorts.
Study Locations (1 sites)
University of Oxford, Oxford, Oxfordshire OX3 9DU United Kingdom
Eligibility Criteria
Inclusion Criteria: * Participant is willing and able to give informed consent for participation in the study * Male or female, aged 30 to 40 years at time of enrolment * Participant previously took part in the ALSPAC study * Able (in the investigator's opinion) and willing to comply with all study requirements * Adequate understanding of verbal and written English Exclusion Criteria: * Pregnant or lactating when they are due to attend for study visit 1 * Less than six months postpartum * Planning to donate blood within two weeks prior to study visit 1 * Any significant disease or disorder which, in the opinion of the investigator, might influence the participant's ability to participate in the study * Evidence of congenital heart disease or significant chronic disease relevant to cardiovascular or metabolic status For exclusion of MRI component only: * Unsuitable for MRI based on participant screening; the participant may still be included in other parts of the study
Conditions Refractory Hypertension or Drug-intolera...
Phase NA
Enrollment 204
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Prospective, multicenter, randomized, controlled, blinded, and superiority - designed; The target population undergoes a screening treatment with prescribed medications for at least 4 weeks. Eligible subjects are randomly assigned to the experimental group and the control group at a ratio of 2:1. The experimental group is treated with the ultrasound nerve ablation catheter and the ultrasound nerve ablation device of Shenzhen Maiwei Medical Technology Co., Ltd., while the control group only undergoes renal arteriography (regarded as a sham operation). Within 6 months after the operation, both groups continue to receive antihypertensive drug treatment with the dosage and types specified during the screening period. The subjects are kept blinded during the study. The relative change values of the average 24 - hour ambulatory systolic blood pressure from the baseline at 6 months after the operation are compared between the two groups.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Procedure: ultrasound renal denervation — Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device

Primary Outcomes

  • The average change value of 24 - hour ambulatory systolic blood pressure (ASBP) relative to the baseline (Six months after surgery)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2025-01-25
Completion: 2030-12
Eligibility
Age: 18 Years – 70 Years
Sex: ALL
Volunteers: false
Enrollment: 204 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shenzhen Pulsecare Medical Technology Co., Ltd.
Contact Information
Study Contact:
Jingfeng J wang, Postdoctoral fellow
020-81332199
wangjingfeng2017@163.com
Jingfeng Wang J Wang
189 2891 6398
wangjingfeng2017@163.com
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Interventions
  • Procedure: ultrasound renal denervation — Treat with an ultrasound nerve ablation catheter and an ultrasound nerve ablation device
Study Locations (1 sites)
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
Eligibility Criteria
Inclusion Criteria: 1. Age between 18 and 70 years old (calculated based on the date of starting standardized medication). 2. After treatment with at least two types of antihypertensive drugs for 4 weeks or more, the clinic systolic blood pressure is ≥140 mmHg and ≤180 mmHg, and the average 24 - hour ambulatory systolic blood pressure is ≥130 mmHg (or the daytime ambulatory systolic blood pressure is ≥135 mmHg). 3. Resting heart rate ≥70 beats per minute without taking beta - blockers (this criterion does not apply to patients taking beta - blockers). 4. The subject agrees to participate in this clinical trial, complies with the follow - up required by the trial protocol, and has voluntarily signed the informed consent form Exclusion Criteria: 1. CTA, MRA, or DSA examination shows that the shape and structure of the unilateral or bilateral renal arteries are not suitable for ablation surgery (renal artery stenosis exceeding 50%, renal artery aneurysm, fibromuscular dysplasia of the renal artery, or the diameter of the main renal artery is less than 3 mm). 2. Having only one kidney or having received a kidney transplant. 3. Having a history of renal artery interventional treatment or renal denervation surgery. 4. Suffering from any condition that may affect the accuracy of blood pressure measurement, such as the upper arm diameter being too large relative to the cuff. 5. Secondary hypertension (excluding apnea syndrome). 6. Glomerular filtration rate (eGFR) \< 45 mL/min/1.73m² (MDRD formula). 7. Having a history of hospitalization due to hypertensive crisis within one year before randomization for enrollment. 8. Suffering from type 1 diabetes. 9. Suffering from primary pulmonary hypertension. 10. Being allergic to contrast agents. 11. Severe cardiac valve stenosis. 12. Cardiac insufficiency (NYHA class III - IV). 13. Hyperthyroidism or hypothyroidism. 14. Requiring mechanical ventilation for assisted breathing (except for nocturnal respiratory support for treating sleep apnea). 15. Acute or severe systemic infection. 16. Having an implantable cardioverter - defibrillator (ICD) or pacemaker. 17. Having obvious symptoms of active peptic ulcer (such as abdominal pain, nausea, vomiting, regurgitation, etc.). 18. Having obvious bleeding tendency and hematological diseases. 19. Having a history of surgery or trauma requiring hospitalization within 30 days before randomization for enrollment. 20. Having a cardiovascular event (stable or unstable angina, myocardial infarction) or cerebrovascular event (stroke, cerebrovascular accident, transient ischemic attack) within 6 months before randomization for enrollment. 21. Pregnant, lactating women, or women planning to become pregnant during the study period. 22. Currently participating in other clinical trials of drugs or medical devices. 23. Other reasons that the investigator deems inappropriate for participation in this study
Conditions Mild Autonomous Cortisol Secretion (MACS...
Phase PHASE4
Enrollment 10
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

To characterize the impact of Isturisa on clinical features and comorbidities associated with MACS. The investigators hypothesize that patients treated with Isturisa will exhibit significantly better metabolic indicators (such as fasting glucose, HbA1c, and lipid profile), blood pressure, weight, body composition and bone mineral density than at Baseline. The investigators also assess the effect of Isturisa on quality of life and psychological symptoms in patients with MACS. The investigators hypothesize that treatment with Isturisa will lead to significant improvements in quality-of-life scores and reductions in depression scores compared to Baseline.

Design

Study type: Interventional Phases: Phase4 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Osilodrostat (Isturisa) — The intervention aims to evaluate the impact of osilodrostat on cardiometabolic outcomes, bone mineral density, body composition, adrenal tumor size or hyperplasia, and biochemical markers of cortisol excess.

Primary Outcomes

  • Change in fasting glucose, HbA1c (Baseline, and then every 3 months up to 2 years)
  • Change in bone mineral density (g/cm²) (Baseline, 1 year, and 2 years)
  • Change in body weight (kg) from baseline during Isturisa treatment (Baseline and every 3 months up to 2 years)
  • Change in lipid profile from baseline during Isturisa treatment (Baseline and every 3 months up to 2 years)
  • Change in body composition (kg) (baseline, 1 year and 2 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE4
Status: Recruiting
Start Date: 2026-02-02
Completion: 2029-03
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 10 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Johns Hopkins University
Collaborators: Recordati Rare Diseases Inc
Principal Investigators:
  • Amir Hamrahian, MD (PRINCIPAL_INVESTIGATOR) - Johns Hopkins University
Contact Information
Study Contact:
Pooneh Jabbaripour Sarmadian, MD
667-208-8367
pjabbar1@jh.edu
Tony Keyes
410-550-6259
akeyes1@jhmi.edu
Amir Hamrahian, MD
410-955-1578
ahamrah1@jhmi.edu
Johns Hopkins University School of Medicine
Interventions
  • Drug: Osilodrostat (Isturisa) — The intervention aims to evaluate the impact of osilodrostat on cardiometabolic outcomes, bone mineral density, body composition, adrenal tumor size or hyperplasia, and biochemical markers of cortisol excess.
Study Locations (1 sites)
Johns Hopkins University School of Medicine, Baltimore, Maryland 21205 United States
Eligibility Criteria
Inclusion Criteria: * Adults aged ≥18 years. * Diagnosis of mild autonomous cortisol secretion (MACS) defined by: * Serum cortisol \>1.8 µg/dL after 1 mg overnight dexamethasone suppression test (DST). * Presence of adrenal adenoma confirmed by imaging (CT or MRI). * Ability to provide informed consent. * Willingness to undergo study procedures including DEXA scan and laboratory assessments. Exclusion Criteria: * Known diagnosis of Cushing's syndrome or overt hypercortisolism. * Current or recent (within 3 months) treatment with glucocorticoids or medications affecting cortisol production (e.g., ketoconazole, metyrapone). * Severe hepatic impairment or renal failure. * Pregnancy or breastfeeding. * Known allergy or contraindication to osilodrostat (Isturisa). * Participation in another interventional clinical trial within the last 30 days. * Any medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or safety.
Conditions Breast Cancer Females
Phase Not Applicable
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

Aromatase inhibitors are the most used endocrine therapy for hormone-positive breast cancer. While there is a clear linear relationship between the duration of aromatase inhibitor use and the cumulative incidence of cardiovascular events and mortality, the underlying mechanisms contributing to this risk remain unknown. This study will characterize the short-term effects of aromatase inhibitor therapy on established and novel health indices for cardiovascular diseases in breast cancer patients. Using a longitudinal case-control design this study will assess the effects of short-term (first 6 months) aromatase inhibitor use in breast cancer patients compared to age- and BMI-matched controls, aiming to determine the cardiovascular, metabolic, and behavioural health impacts of endocrine treatment during this early period. Specifically, our objectives are as follows: 1. To examine the effects of aromatase inhibitor therapy on early risk indicators for cardiovascular disease in the peripheral vasculature and heart, including blood biomarkers (lipids), blood pressure, aortic and peripheral stiffness, carotid artery stiffness and intima media thickness, endothelial function, and left ventricular ejection fraction, longitudinal strain, volumes, and mass, including the responsiveness of the cardiovascular system to an oral glucose tolerance test, in breast cancer survivors compared to controls. 2. To examine the effects of aromatase inhibitor therapy on factors related to cerebrovascular health, autonomic regulation, and cognitive function, including BDNF, heart rate variability, cerebrovascular function in response to a supine-sit-stand maneuver and squatting challenge, and a core battery of cognitive function tests, in breast cancer survivors compared to controls. 3. To examine the effects of aromatase inhibitor therapy on body composition and bone mineral density, along with assessments of glycemic regulation in response to an oral glucose tolerance test and in 24h periods of free-living (continuous glucose monitoring), in breast cancer survivors compared to controls. 4. To examine the effects of aromatase inhibitor therapy on lifestyle factors (behavioural), including diet, physical activity (including cardiorespiratory fitness), sleep, stress, and quality of life, in breast cancer survivors compared to controls. The investigators hypothesize that cardiovascular and metabolic health outcomes will be similar between breast cancer survivors and controls at baseline but will deteriorate relative to controls within the first 6 months of aromatase inhibitor therapy.

Design

Study type: Observational Observational model: Case Control Time perspective: Prospective

Interventions / Regimen

  • Other: N/A (Usual Care) — BC survivors will be using aromatase inhibitors as prescribed in their usual care treatment.

Primary Outcomes

  • Aortic Stiffness (Baseline, 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-06-06
Completion: 2026-12-30
Eligibility
Age: Not reported
Sex: FEMALE
Volunteers: true
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: University of Toronto
Collaborators: Cancer Research Society, Canadian Institutes of Health Research (CIHR), Princess Margaret Hospital, Canada
Contact Information
Study Contact:
Amy A. Kirkham, PhD
416-946-4069
amy.kirkham@utoronto.ca
Amy A. Kirkham, PhD
416-946-4069
amy.kirkham@utoronto.ca
University of Toronto
Interventions
  • Other: N/A (Usual Care) — BC survivors will be using aromatase inhibitors as prescribed in their usual care treatment.
Study Locations (1 sites)
University of Toronto, Toronto, Ontario M5S2C9 Canada
Eligibility Criteria
Inclusion Criteria: Case group: * Biologically female * Post-menopausal with natural (no bilateral oophorectomy) amenorrhea for at least 1 year * If using hormone replacement therapy, limit of a maximum of 3 years of treatment but not within the last 6 months. * Diagnosis of stage I, II, or III breast cancer * Hormone receptor positive breast cancer * HER negative (ER+/PR+/HER-) breast cancer * Confirmed to start aromatase inhibitor therapy for the first time in next 2-3 months * Received surgery/radiation therapies Control group: * Biologically female * Post-menopausal with natural (no bilateral oophorectomy) amenorrhea for at least 1 year * If using hormone replacement therapy, limit of a maximum of 3 years of treatment but not within the last 6 months. Exclusion Criteria: * Previous treatment using tamoxifen endocrine therapy in a pre-or peri-menopausal setting * Major signs or symptoms of cardiovascular diseases, diabetes, or renal disease (taken from the American College of Sports Medicine's Guidelines for Exercise Testing and Prescription 11th edition Table 2.1: pain or discomfort in the chest, neck, jaw, arms with rest or exercise, shortness of breath at rest or with mild exertion, dizziness or syncope, loss of balance or passing out, ankle edema, palpitations or tachycardia, intermittent claudication, known heart murmur, unusual fatigue with usual activities.) * American Heart Association's absolute or relative contraindications for symptom-limited maximal exercise testing (myocardial infarction, aortic or coronary artery stenosis, heart failure, pulmonary embolism or deep vein thrombosis, inflammation of the heart (myocarditis, pericarditis, and/or endocarditis), uncontrolled cardiac arrythmia, advanced or complete electrical heart block, stroke or transient ischemia attack, blood pressure \>200mmHg/100mmHg, a cancer diagnosis other than skin cancer) * Unable to provide informed consent or communicate in English * Mobility limitations to exercise testing (i.e., wheelchair, walker use, limp impeding walking) * Extreme claustrophobia
Conditions Breast Cancer, Drug-Related Side Effects...
Phase NA
Enrollment 124
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This study is a multicenter randomized controlled trial designed to evaluate the effectiveness of a structured telenursing intervention in patients with breast cancer receiving cyclin-dependent kinase (CDK) inhibitor therapy. Patients undergoing treatment with CDK inhibitors frequently experience adverse effects that may negatively impact treatment adherence, quality of life, and clinical outcomes. Early detection and timely management of these side effects are essential to optimize therapy and reduce complications, including unplanned hospitalizations and treatment interruptions. In this study, participants are randomly assigned to one of two groups: standard care or standard care plus a structured telenursing follow-up program. The intervention consists of scheduled remote contacts (telephone or video consultations) conducted by trained nursing staff at predefined time points during treatment. These contacts aim to monitor symptoms, provide education, reinforce adherence, and facilitate early identification and management of treatment-related toxicities. The primary objective of the study is to assess whether the telenursing intervention reduces the incidence and severity of treatment-related adverse events compared to standard care alone. Secondary objectives include evaluating its impact on emergency department visits, hospitalizations, treatment adherence, dose intensity, and patient-reported outcomes. The study is currently recruiting participants across multiple centers. Results from this trial may provide evidence to support the integration of structured telenursing programs into routine oncology care, with the potential to improve patient safety, treatment continuity, and overall clinical outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Structured Telenursing Follow-up — A structured telenursing follow-up program consisting of scheduled telephone or video consultations conducted by trained oncology nurses during treatment with CDK inhibitors. The intervention includes systematic symptom assessment, patient education, adherence support, and early identification and management of treatment-related adverse events.
  • Other: Standard Nursing Care — Routine clinical and nursing care provided according to standard local practice, including scheduled outpatient visits and patient-initiated contacts as needed.

Primary Outcomes

  • Incidence of treatment-related adverse events assessed by CTCAE (v5.0) (From treatment initiation up to 6 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-04-09
Completion: 2028-09
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 124 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Azienda Sanitaria Locale di Asti
Principal Investigators:
  • MANUELA CANICATTI', RN, MSc, PhD(c) (PRINCIPAL_INVESTIGATOR) - ASL AT
  • Michela PIREDDA, RN, MSc, PhD (STUDY_DIRECTOR) - University of Rome Tor Vergata, Italy
Contact Information
Study Contact:
MANUELA CANICATTI', RN, MSc, PhD(c)
+39 3297278131
mcanicatti@asl.at.it
MANUELA CANICATTI', RN, MSc, PhD(c)
+39 03297278131
mcanicatti@asl.at.it
Cardinal Massaia Hospital - S.C. Oncology, Azienda Sanitaria Locale AT (ASL AT)
MANUELA CANICATTi', RN, MSc, PhD(c)
Cardinal Massaia Hospital - S.C. Oncology, Azienda Sanitaria Locale AT (ASL AT)
Interventions
  • Behavioral: Structured Telenursing Follow-up — A structured telenursing follow-up program consisting of scheduled telephone or video consultations conducted by trained oncology nurses during treatment with CDK inhibitors. The intervention includes systematic symptom assessment, patient education, adherence support, and early identification and management of treatment-related adverse events.
  • Other: Standard Nursing Care — Routine clinical and nursing care provided according to standard local practice, including scheduled outpatient visits and patient-initiated contacts as needed.
Study Locations (1 sites)
Cardinal Massaia Hospital - S.C. Oncology, Azienda Sanitaria Locale AT (ASL AT), Asti, ASTI 14100 Italy
Eligibility Criteria
Inclusion Criteria: * Female patients aged ≥18 years * Histologically confirmed breast cancer * Ongoing treatment with CDK 4/6 inhibitors (e.g., palbociclib, ribociclib, abemaciclib) * Ability to understand and provide informed consent * Access to a telephone or digital communication device for telenursing follow-up Exclusion Criteria: * Inability to comply with the study procedures * Cognitive impairment or psychiatric conditions interfering with participation * Participation in another interventional clinical trial that may affect study outcomes * Severe comorbidities limiting life expectancy or follow-up
Conditions Estrogen Receptor-Positive Breast Carcin...
Phase PHASE2
Enrollment 80
Locations 23 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This phase II trial tests how well Reishi mushroom extract works in treating fatigue and/or joint/muscle pain (arthralgias/myalgias) in patients with breast cancer on aromatase inhibitors. Fatigue and arthralgias/myalgias are common symptoms in breast cancer patients taking aromatase inhibitors (AI). Given the long duration of AI treatment for some women (up to 10 years), these symptoms can significantly impact quality of life and premature discontinuation of AIs, a beneficial medication. Reishi mushrooms are among several medicinal mushrooms that have been used for hundreds of years, mainly in Asian countries, to help enhance the immune system, reduce stress, improve sleep, and lessen fatigue. Reishi mushroom extracts have not been studied explicitly for treatment-induced arthralgias/myalgias, but have been shown to improve quality of life, muscular strength, pain, and flexibility. Information from this study may help researchers determine the effect of Reishi mushroom extract on fatigue and arthralgias/myalgias in breast cancer patients receiving an AI.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Crossover Primary purpose: Supportive Care Masking/blinding: Double

Interventions / Regimen

  • Dietary Supplement: Mushroom Extract — Given Reishi mushroom extract PO
  • Drug: Placebo Administration — Given PO
  • Other: Quality-of-Life Assessment — Ancillary studies
  • Other: Questionnaire Administration — Ancillary studies

Primary Outcomes

  • Change in fatigue scores (Baseline to end of four weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-10-18
Completion: 2027-09-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 80 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Mayo Clinic
Principal Investigators:
  • Stacy D. D'Andre, MD (PRINCIPAL_INVESTIGATOR) - Mayo Clinic in Rochester
Contact Information
Study Contact:
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Clinical Trials Referral Office
855-776-0015
mayocliniccancerstudies@mayo.edu
Mayo Clinic Health System in Albert Lea
Mina Hanna, MD
Mayo Clinic Health System in Albert Lea
Interventions
  • Dietary Supplement: Mushroom Extract — Given Reishi mushroom extract PO
  • Drug: Placebo Administration — Given PO
  • Other: Quality-of-Life Assessment — Ancillary studies
  • Other: Questionnaire Administration — Ancillary studies
Study Locations (23 sites)
Mayo Clinic Health System in Albert Lea, Albert Lea, Minnesota 56007 United States
Essentia Health Baxter Clinic, Baxter, Minnesota 56425 United States
Sanford Joe Lueken Cancer Center, Bemidji, Minnesota 56601 United States
Essentia Health Saint Joseph's Medical Center, Brainerd, Minnesota 56401 United States
Essentia Health Deer River Clinic, Deer River, Minnesota 56636 United States
Essentia Health Saint Mary's - Detroit Lakes Clinic, Detroit Lakes, Minnesota 56501 United States
Essentia Health Cancer Center, Duluth, Minnesota 55805 United States
Essentia Health Ely Clinic, Ely, Minnesota 55731 United States
Essentia Health Fosston, Fosston, Minnesota 56542 United States
Fairview Grand Itasca Clinic & Hospital, Grand Rapids, Minnesota 55744 United States
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years * History of breast cancer, estrogen receptor positive (ER+), Her 2 positive or negative * Fatigue ≥ 4/10 * Currently post-menopausal (as defined by National Comprehensive Cancer Network (version 4.2024), taking any aromatase inhibitor in the curative setting and planning to be on such for at least 8 weeks after registration. \[Patients on concurrent ovarian suppression (such as with leuprolide acetate, goserelin) are allowed\]; CDK 4/6 inhibitors abemaciclib, ribociclib ARE allowed * Prior treatment: last chemotherapy ≥ 90 days prior to randomization (if treated with chemotherapy) * On a stable dose of pain medications if pain medications are being regularly used. (i.e., no change in dosage in the past 30 days) * If on supplements, must be on stable dose with no plan to change; not on or planning any acupuncture or other specific supportive modalities for fatigue or AI arthralgias * Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2 * White blood cell count (WBC) ≥ 3,000/mm\^3 (obtained ≤ 30 days prior to randomization) * Hemoglobin ≥ 10 g/dL (obtained ≤ 30 days prior to randomization) * Platelet count ≥ 100,000/mm\^3 (obtained ≤ 30 days prior to randomization) * Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 30 days prior to randomization) * Alanine aminotransferase (ALT) or aspartate transaminase (AST) ≤ 1.2 x ULN (obtained ≤ 30 days prior to randomization) * Prothrombin time (PT)/activated partial thromboplastin time (aPTT) ≤ 1.5 x ULN (obtained ≤ 30 days prior to randomization) * Negative pregnancy test done ≤ 7 days prior to registration, for persons on concurrent ovarian suppression only * Provide informed consent * Ability to complete questionnaires * Willing to return to enrolling institution during the active monitoring phase of the study * Patients who have had a recent surgery or procedure should be healed and cleared by their clinician and/or surgeon per local standards, prior to registration Exclusion Criteria: * Other known uncontrolled medical conditions causing fatigue such as untreated thyroid disease, depression, fibromyalgia, chronic fatigue syndrome, infection, autoimmune disease, or active/untreated hepatitis * Allergy to mushrooms * On anticoagulation medication or aspirin or having a known bleeding disorder * On any specific medication for fatigue (e.g., methylphenidate) * Metastatic cancer diagnosis (history of nodal metastases is allowed) * Chronic steroid use, unless on physiologic replacement doses * Current use of any medical mushrooms * On medications for diabetes * History of symptomatic hypotension * Taking CYP3A4, CYP2D6 sensitive substrates which can be located at the following link: https://www.fda.gov/drugs/drug-interactions-labeling/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems * Drugs which exhibit either \>20% inhibition or \>20% induction of CYP2E1 in vivo, such as: Acetaminophen, Dapsone, Enflurane, Halothane, Isoflurane, \& Theophylline * Taking olaparib * Any of the following because this study involves an agent that has unknown genotoxic, mutagenic and teratogenic effects: * Pregnant persons * Nursing persons * Persons on concurrent ovarian suppression who are unwilling to employ adequate contraception (e.g., hormonal methods, barrier methods, intrauterine device, abstinence) * Planned surgery or procedure during time on study and ≤ 14 days after last dose, due to bleeding risks
Conditions First-line Treatment of HER2-positive Re...
Phase PHASE3
Enrollment 880
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This is a randomized, controlled, open-label, multicenter, phase Ш clinical study designed to compare the efficacy and safety of KN026 in combination with HB1801 to trastuzumab in combination with pertuzumab and docetaxel in the first-line treatment of subjects with HER2-positive recurrent or metastatic breast cancer. The statistical assumption for this study is superiority. The primary study endpoint was PFS as assessed by Blinded Independ Review Committee (BIRC).

Design

Study type: Interventional Phases: Phase3 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Recombinant Humanized Bispecific antibody against HER2,KN026 — IV infusion
  • Drug: HB1801 — IV infusion
  • Drug: Pertuzumab — 840 mg loading dose followed by 420 mg per cycle, D1 Q3W, IV infusion
  • Drug: Trastuzumab — 8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion
  • Drug: Docetaxel — 75 mg/m\^2, D1 Q3W, IV infusion

Primary Outcomes

  • Free-progression survival (PFS) as evaluated by BIRC (RECIST1.1). (Up to approximately 4 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE3
Status: Recruiting
Start Date: 2023-07-23
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 880 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Shanghai JMT-Bio Inc.
Contact Information
Study Contact:
Clinical Trials Information Group Officer
+86-0311-69085587
ctr-contact@mail.ecspc.com
fenglin She
18301190515
shefenglin@cspc.cn
Clinical Trials Information Group Officer
+86-0311-69085587
ctr-contact@mail.ecspc.com
Clinical Trials Information Group
Interventions
  • Drug: Recombinant Humanized Bispecific antibody against HER2,KN026 — IV infusion
  • Drug: HB1801 — IV infusion
  • Drug: Pertuzumab — 840 mg loading dose followed by 420 mg per cycle, D1 Q3W, IV infusion
  • Drug: Trastuzumab — 8 mg/kg loading dose followed by 6 mg/kg per cycle, D1 Q3W, IV infusion
  • Drug: Docetaxel — 75 mg/m\^2, D1 Q3W, IV infusion
Study Locations (1 sites)
Clinical Trials Information Group, Beijing, chaoyang China
Eligibility Criteria
Key Inclusion Criteria: * Voluntarily enrolled in this study and signed an informed consent form (ICF). * Age ≥ 18 years. * Recurrent or metastatic breast cancer confirmed by histology and/or cytology. * Latest tumor tissue sample confirmed as HER2 positive by central laboratory testing. * No prior systemic chemotherapy and/or HER2-targeted therapy for recurrent or metastatic breast cancer. * Eastern Cooperative Oncology Group (ECOG) physical status score of 0 - 1. * Presence of lesion (RECIST 1.1). * Adequate organ and bone marrow function Key Exclusion Criteria: * Ineligible for any of the agents on the study * Untreated or unstable parenchymal metastases, spinal cord metastases or compression, or carcinomatous encephalitis. * Pregnant or lactating women. * Presence of other circumstances that may interfere with the subject's participation in the study procedures or are inconsistent with the maximum benefit of the subject's participation in the study or affect the results of the study: e.g., history of mental illness, drug or substance abuse, any other disease or condition of clinical significance, etc.
Conditions TNBC, Adjuvant Therapy, Lymph Node Posit...
Phase NA
Enrollment 59
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

This study is a prospective, multicenter, phase II clinical trial designed to evaluate the efficacy and safety of postoperative chemotherapy combined with QL1706 in patients with high-risk triple-negative breast cancer. After enrollment, participants will receive 8 cycles of chemotherapy combined with QL1706. The standard chemotherapy regimen is the AC-T regimen (4 cycles of epirubicin plus cyclophosphamide, followed by 4 cycles of a taxane) - a Category I recommendation in the 2025 CSCO guidelines. The final choice of chemotherapy regimen is at the investigator's discretion. Starting from cycle 9, participants will receive QL1706 monotherapy as maintenance treatment. Dosing will continue until protocol-defined treatment discontinuation criteria are met, the participant experiences intolerable toxicity, or the participant withdraws informed consent. The maximum number of QL1706 dosing cycles is 17. After completing treatment, participants will continue to undergo post-treatment safety follow-up and survival follow-up. For participants who discontinue treatment for reasons other than disease progression or death, tumor progression follow-up will also be conducted after treatment ends. After enrollment, safety assessments will be performed every 3 weeks, and imaging evaluations will be performed every 12 weeks (±7 days) until confirmed disease progression per RECIST v1.1, initiation of another new anti-cancer therapy, withdrawal of informed consent, or death, whichever occurs first.

Design

Study type: Interventional Phases: Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy — After enrollment, participants will receive 8 cycles of chemotherapy combined with QL1706. The standard chemotherapy regimen is the AC-T regimen (4 cycles of epirubicin plus cyclophosphamide, followed by 4 cycles of a taxane) - a Category I recommendation in the 2025 CSCO guidelines. Starting from cycle 9, participants will receive QL1706 monotherapy as maintenance treatment. Dosing will continue until protocol-defined treatment discontinuation criteria are met, the participant experiences intolerable toxicity, or the participant withdraws informed consent. The maximum number of QL1706 dosing cycles is 17.

Primary Outcomes

  • 3-year disease-free survival rate (DFS%) (within a 3-year follow-up period)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-06-05
Completion: 2030-12-31
Eligibility
Age: 18 Years – 75 Years
Sex: ALL
Volunteers: false
Enrollment: 59 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: The First Affiliated Hospital with Nanjing Medical University
Collaborators: Qilu Pharmaceutical Co., Ltd.
Contact Information
Study Contact:
Xiaoan Liu
+86 138 0517 0249
liuxiaoan@126.com
Xiaoan Liu
+86 138 0517 0249
liuxiaoan@126.com
The First Affiliated Hospital of Nanjing Medical University
Xiaoan Liu
The First Affiliated Hospital of Nanjing Medical University
Interventions
  • Drug: Aipaluoli-tovorilimab plus AC-T chemotherapy as postoperative adjuvant therapy — After enrollment, participants will receive 8 cycles of chemotherapy combined with QL1706. The standard chemotherapy regimen is the AC-T regimen (4 cycles of epirubicin plus cyclophosphamide, followed by 4 cycles of a taxane) - a Category I recommendation in the 2025 CSCO guidelines. Starting from cycle 9, participants will receive QL1706 monotherapy as maintenance treatment. Dosing will continue until protocol-defined treatment discontinuation criteria are met, the participant experiences intolerable toxicity, or the participant withdraws informed consent. The maximum number of QL1706 dosing cycles is 17.
Study Locations (1 sites)
The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210000 China
Eligibility Criteria
Inclusion Criteria: 1. The participant voluntarily joins this study and signs the informed consent form. 2. Female breast cancer participants aged ≥18 and ≤75 years, with a histologically or cytologically confirmed diagnosis of TNBC (IHC 0, IHC 1+, or IHC 2+/ISH-) based on the most recent biopsy or other pathological specimen, according to the latest ASCO/CAP guidelines. Patients with low ER or PR expression (1%-10%) may also be included in this study. 3. Patients with high-risk TNBC (defined as lymph node-positive). 4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 5. Agree to provide intraoperatively obtained tumor histopathological specimens (FFPE, at least 5 sections) for biomarker testing. 6. Expected survival ≥3 months. 7. Function of vital organs meets the following requirements (use of any blood components or cell growth factors within 14 days before the first dose is not allowed): * Absolute neutrophil count ≥1.5×10⁹/L; * Platelet count ≥100×10⁹/L; * Hemoglobin ≥90 g/L; * Serum albumin ≥30 g/L; * Thyroid-stimulating hormone (TSH) ≤1×ULN (if abnormal, FT3 and FT4 levels should also be assessed; if FT3 and FT4 are within normal range, the patient may be enrolled); * Serum total bilirubin ≤1.5×ULN; * ALT and AST ≤2.5×ULN; in the presence of liver metastases, ALT and AST ≤5×ULN; * ALP ≤2.5×ULN (in patients with liver or bone metastases, ALP ≤5×ULN); * Serum creatinine ≤1.5×ULN; * International normalized ratio (INR) ≤1.5×ULN (not receiving anticoagulation therapy). 8. Female participants who are not surgically sterilized or are of childbearing potential must use a medically approved contraceptive method (such as an intrauterine device, contraceptive pill, or condom) during the study treatment period and for 3 months after the end of the study treatment. Female participants of childbearing potential who are not surgically sterilized must have a negative serum or urine HCG test within 7 days before the first dose and must not be lactating. Exclusion Criteria: 1. Presence of any active autoimmune disease or history of autoimmune disease (e.g., including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, vasculitis, nephritis, hyperthyroidism); however, participants with the following conditions are allowed to enroll: vitiligo, psoriasis, alopecia not requiring systemic treatment; well-controlled type I diabetes mellitus; hypothyroidism stable on hormone replacement; childhood asthma that has completely resolved and requires no intervention in adulthood; asthma requiring bronchodilators for medical intervention is excluded. 2. Current use of immunosuppressants or systemic corticosteroid therapy for immunosuppressive purposes (dose \>10 mg/day prednisone or equivalent) within 2 weeks prior to enrollment. 3. History of severe hypersensitivity reaction to other monoclonal antibodies. 4. Prior discontinuation of anti-PD-1/PD-L1 antibody therapy due to related toxicity. 5. Known history or evidence of interstitial lung disease or active non-infectious pneumonitis. 6. History of CNS metastases or current central nervous system (CNS) metastases. Baseline imaging to rule out brain metastases is not mandatory. Patients with unknown CNS metastasis status but with any clinical signs suggestive of CNS metastases are eligible only if CT and/or MRI scans rule out CNS metastases. 7. Previous history of other malignancies (except for patients with non-melanoma skin cancer or carcinoma in situ of the cervix, who are eligible; patients with other prior malignancies must have been disease-free for at least 3 years). 8. Hypertension poorly controlled with antihypertensive medication (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg); achieving the above parameters with antihypertensive treatment is allowed. History of hypertensive crisis or hypertensive encephalopathy. 9. Within 6 months before first dose, known history of unstable angina, myocardial infarction (MI), or chronic heart failure (CHF), or known history of clinically significant arrhythmia requiring antiarrhythmic therapy (except stable atrial fibrillation), or left ventricular ejection fraction \<50%. 10. Current thrombolytic or anticoagulant therapy; prophylactic use of low-dose aspirin or low-molecular-weight heparin is permitted. 11. Presence of pleural effusion, ascites, or pericardial effusion requiring drainage; patients may be enrolled if clinically stable after drainage as assessed by the investigator. 12. Arterial/venous thrombotic events occurring within 6 months before enrollment, such as cerebrovascular accident (including transient ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein thrombosis, and pulmonary embolism. 13. Major vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months before start of study treatment. 14. Major surgery (excluding diagnostic procedures) within 4 weeks before start of study treatment, or anticipated need for major surgery during the study. 15. Urinalysis showing urine protein ≥++ and confirmed 24-hour urine protein \>1.0 g. 16. Prior radiotherapy (except palliative radiotherapy for bone lesions), chemotherapy, or surgery (except biopsy) with completion (last dose) less than 4 weeks before the first study dose; last dose of antibody therapy less than 4 weeks before first study dose; molecular targeted therapy (including oral targeted drugs from other clinical trials) less than 5 half-lives before first study dose, or adverse reactions from prior treatment (excluding alopecia) not recovered to ≤CTCAE grade 1. 17. Active infection, unexplained fever ≥38.5°C within 7 days before dosing, or baseline white blood cell count \>15×10⁹/L. 18. Congenital or acquired immunodeficiency (e.g., HIV infection); hepatitis B surface antigen (HBsAg) positive with HBV DNA ≥2000 IU/mL; or hepatitis C virus antibody positive. 19. Prior treatment with immune checkpoint inhibitors such as anti-PD-1, PD-L1, or anti-CTLA-4. 20. Receipt of live vaccine within 4 weeks before first study dose or possible vaccination during the study period. 21. As judged by the investigator, any other condition that may affect the study results or cause forced premature termination of the study, such as alcoholism, drug abuse, other serious diseases (including psychiatric illness) requiring concomitant treatment, severe laboratory abnormalities, or family/social factors that may affect patient safety. 22. Women who are pregnant or breastfeeding.
Conditions Breast Cancer, Colon Cancer
Phase NA
Enrollment 100
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-10-09
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this interventional study is to test the heart-rate variability biofeedback intervention (HRV BI) in 2 cohorts of patients. Cohort A will evaluate the effect of the addition of HRV BI in patients with breast cancer treated in the neoadjuvant setting (vs. standard of care alone, SOC) followed by local therapy (surgery +/-radiotherapy). Cohort B will evaluate the effect of the addition of HRV BI in patients with colon cancer after surgery in the adjuvant setting (vs. standard of care alone, SOC).

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Supportive Care Masking/blinding: None

Interventions / Regimen

  • Behavioral: Heart-rate variability biofeedback intervention — Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months

Primary Outcomes

  • Primary endpoint - inflammation (36 months)
  • Primary endpoint - QoL (36 months)
  • Primary endpoint - executive functions (36 months)
  • Primary endpoint- salivary cortisol slopes (36 months)
  • Primary endpoint- sleep quality (36 months)
  • Primary endpoint - heart rate variability (HRV) (36 months)
  • Primary endpoint - Working memory (36 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2024-03-15
Completion: 2029-03-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 100 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Comenius University
Contact Information
Study Contact:
Luba Hunáková
00421290119943
mailto:luba.hunakova@fmed.uniba.sk
Bela Mrinakova, MD
00421232249111
bela.mrinakova@ousa.sk
St. Elizabeth Cancer Institute
Miriam Hancinova, MD
00421232249111
miriam.hancinova@ousa.sk
St. Elizabeth Cancer Institute
Interventions
  • Behavioral: Heart-rate variability biofeedback intervention — Daily deep paced breathing 3-times (minimum 7 minutes each) for 3 months
Study Locations (1 sites)
St. Elizabeth Cancer Institute, Bratislava, 81250 Slovakia
Eligibility Criteria
Inclusion Criteria: 1. Patients older than 18 years. 2. Pathologically confirmed breast cancer indicated for neoadjuvant systemic treatment or colon cancer after curative surgery indicated for adjuvant systemic treatment. 3. Adequate renal functions: measured or calculated (by Cockcroft formula) creatinine clearance \> 60 ml/min. 4. Absolute granulocytes count ≥ 1,500/mm3, platelets ≥ 100,000 mm3, bilirubin ≤ 1.5x the upper limit of normal value. 5. Adequate liver functions defined by AST (Aspartate aminotransferase) and ALT (Alanine transaminase) ≤ 3xUNL (upper normal of limit). 6. Basic computer skills of patient or his family member. 7. Signed informed consent. Exclusion Criteria: 1. Previous chemotherapy. 2. Previous malignancy, except for basal-cell carcinoma of the skin within last 5 years. 3. Patients with know primary immunodeficiency and patients infected by the Human Immunodeficiency Virus (HIV). 4. Patient receiving long term corticosteroid treatment, anti-arrhythmic drugs and opioids who can not withdraw the treatment for the period of application of the heart rate variability (HRV) biofeedback training. 5. Patients with diabetes mellitus, cardiac arrhythmia, cardiac pacemaker implant. 6. Patients who do not fit inclusion criteria.